---
title: "CRDL: Phase III trial of an oral therapy for recurrent pericarditis nears readout, with broad commercial ambitions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295553195.md"
description: "A pivotal phase III trial is underway for an oral, non-immunosuppressive therapy targeting recurrent pericarditis, with strong efficacy signals and a robust trial design. Commercial plans focus on specialty distribution, competitive pricing, and expansion into heart failure and myocarditis.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-11T14:51:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295553195.md)
  - [en](https://longbridge.com/en/news/295553195.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295553195.md)
generator: "portal-rs"
---

# CRDL: Phase III trial of an oral therapy for recurrent pericarditis nears readout, with broad commercial ambitions

A pivotal phase III trial is underway for an oral, non-immunosuppressive therapy targeting recurrent pericarditis, with strong efficacy signals and a robust trial design. Commercial plans focus on specialty distribution, competitive pricing, and expansion into heart failure and myocarditis.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRDL.US](https://longbridge.com/en/quote/CRDL.US.md)

## Related News & Research

- [Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/297043318.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [TCRX: In vivo TCR therapies for solid tumors advance to IND-enabling stage, with phase I trial set for Q4 2027](https://longbridge.com/en/news/297802700.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**